Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

7Total
Not Applicable (3)
Early P 1 (3)
P 1 (1)

Trial Status

Recruiting3
Not Yet Recruiting2
Terminated1
Withdrawn1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07655453Not ApplicableNot Yet RecruitingPrimary

Early Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of STR-P005

NCT07049081Phase 1TerminatedPrimary

A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases

NCT07605637Not ApplicableNot Yet RecruitingPrimary

Early Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of STR-P005

NCT07448298Early Phase 1RecruitingPrimary

A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases

NCT07095075Early Phase 1RecruitingPrimary

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases

NCT07193667Not ApplicableRecruitingPrimary

CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease

NCT06866080Early Phase 1WithdrawnPrimary

A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases

Showing all 7 trials

Research Network

Activity Timeline